EMEA-001613-PIP01-14-M04
Key facts
Active substance |
tezepelumab
|
Therapeutic area |
Pneumology-allergology
|
Decision number |
P/0012/2020
|
PIP number |
EMEA-001613-PIP01-14-M04
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
Treatment of asthma
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
AstraZeneca AB (Sweden)
Tel. +46 855326000 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|